Short Versus Standard Dental Implants: Clinical and Biomarker Outcomes

ConditionPeri-Implant Mucositis

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-70

SponsorInonu University

About this trial

This study compares two types of dental implants, short implants (6 millimeters or less in length) and standard implants (longer than 8 millimeters), to evaluate their effect on the health of the gum and bone tissue surrounding the implant. Approximately 40 patients receiving a total of 80 dental implants will be followed. Researchers will assess clinical signs of gum health around the implants, measure specific protein levels (biomarkers) in the fluid surrounding the implants associated with gum disease. The goal of this study is to determine whether implant length affects the risk of inflammation or infection around dental implants, which may help guide treatment decisions in the future.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Systemically healthy adults aged 18-70 years.

Presence of at least one short (≤6 mm) and/or standard (>8 mm) dental implant in function for at least 2 years.

Patients presenting to the Department of Periodontology, Faculty of Dentistry, Inonu University, for routine dental examination.

For the peri-implant health group: absence of clinical signs of inflammation (redness, edema, or suppuration), absence of bleeding on probing (BOP), probing pocket depth (PPD) ≤5 mm, full-mouth BOP <10%, no radiographic evidence of pathological peri-implant bone loss, and no clinical implant mobility.

Disqualifiers

Age younger than 18 years or older than 70 years.

Presence of any systemic disease.

Immune system disorders or use of immunosuppressive medications.

Requirement for antibiotic prophylaxis before dental procedures.

Trial population

Adult patients presenting to the Department of Periodontology, Faculty of Dentistry, Inonu University, for routine dental check-up, who have at least one short (≤6 mm) and/or standard (\>8 mm) dental implant in function for at least 2 years.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

40 Participants

are grouped into 2 trial groups

Group A: Short implant group

Group B: Standard Implant Group

Trial outcomes

Primary outcomes

Change in Peri-Implant Crevicular Fluid RANKL Level

Receptor activator of nuclear factor kappa-B ligand (RANKL) levels in peri-implant crevicular fluid (PICF) will be measured using enzyme-linked immunosorbent assay (ELISA) and compared between short and standard implant groups.

Time frame